Diabetes - Renal function - What are the special problems?

Basic Research in Cardiology

Volumn 93, Issue 2 SUPPL., 1998, Pages 125-130

  Ritz, E ^a   Miltenberger Miltenyi, G ^a   Wagner, J ^a   Rychlik, I ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Diabetes mellitus; Diabetic nephropathy; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; PERINDOPRIL; RAMIPRIL; VALSARTAN;

ANIMAL MODEL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FAILURE; MICROALBUMINURIA; NONHUMAN; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; INCIDENCE; KIDNEY; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031793105     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s003950050237     Document Type: Article

References (50)

1. Allen TJ, Cooper ME, Gilbert RE, Winikoff J, Skinni SL, Jerums G (1996) Serum total renin is increased before microalbuminuria in diabetes. Kidney Intern 50 (3): 902-907 (Pubitemid 26302679)
2. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME (1997) Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 46 (10): 1612-1618
3. Biesenbach G, Janko O, Zazgornik J (1994) Similar rate of progression of the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 9: 1097-1102 (Pubitemid 24254075)
4. Björck S (1990) The renin angiotensin system in diabetes mellitus. Aphysiological and therapeutic study. Scand J Urol Nephrol 126 (suppl): 1-51
5. Cassis LA (1992) Downregulation of the renin-angiotensin system in streptozotocindiabetic rats. Am J Physiol 262: E105- E109
6. Christlieb AR, Kaldany AD, D'Elia JA (1976) Plasma renin activity and hypertension in diabetes mellitus. Diabetes 25: 969-974 (Pubitemid 8071014)
7. Correa-Rotter R, Hostetter TH, Rosenberg ME (1992) Renin and angiotensin gene expression in experimental diabetes mellitus. Kidney Int 41: 796-804
8. Craven PA, DeRubertis FR, Melhelm M (1997) Nitric oxide in diabetic nephropathy. Kidney Int Suppl 60: S46-53
9. Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT (1982) The kidney in maturity onstet diabes mellitus: A clinical study of 510 patients. Kidney Intern 21: 730-738 (Pubitemid 12124305)
10. Forsblom C, Trenkwalder P, Dahl K, Mulder H (1997) Candesartan cilexetil, a novel angiotensin II antagonist reduces microalbuminuria in patients with type II diabetes mellitus and mild hypertension. J Hypertens 15 (suppl 4): 113
11. Forsblom C, Trenkwalder P, Dahl K, Mulder H (1997) Candesartan cilexetil, a novel angiotensin II antagonist reduces microalbuminuria in patients with type II diabetes mellitus and mild hypertension. J Hypertens 10 (4): 86A
12. Gansevoort RT, de Zeeuw D, de Jong PE (1994) Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Intern 45: 861-867 (Pubitemid 24094500)
13. Hasslacher C, Ritz E, Wahl P, Michael C (1989) Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 4: 859-863 (Pubitemid 20031053)
14. Jost Vu E, Horton R, Antonipillai I (1992) Altered regulation of renin secretion by insulinlike growth factors and angiotensin II in diabetic rats. Diabetes 41: 1100-1105
15. Kato S, Luyckx VA, Lee KW, Troy JL, Brenner BM, Mackenzie HS (1997) Inhibition of renin-angiotensin system suppresses gene expression of cytokines and growth factors in s treptozotocin-treated diabetic rats. J Am Soc Nephrol A2987: 640A
16. Kawazu S, Tomono S, Shimuzu M, Kato N, Ohno T, Ishii C, Murata K, Watanabe T, Negishi K, Suzuki M (1994) The relationship between early diabetic nephropathy and control of plasma glucose in noninsulin- dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8 year follow-up study. J Diabet Complications 8: 13-17 (Pubitemid 24371436)
17. Kennefick TM, Anderson S. Role of angiotensin II in diabetic nephropathy (1997) Semin Nephrol 17 (5): 441-447 (Pubitemid 27398456)
18. Kon V, Fogo A, Ichikawa I, Hellings AE, Bills T (1993) Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Intern 44: 545-550 (Pubitemid 23265222)
19. Laffel L, Price D, Porter L, Hollenberg N (1997) Appropriate intrarenal angiotensin II action in patients with insulin-dependent diabetes mellitus (IDDM). J Am Soc Nephrol 8: 1606A
20. Lewis EJ, Hunsicker LG, Brain RP, Rhode RD (1993) The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. The Collaborativ Study Group. N Engl J Med 329: 1456-1462 (Pubitemid 23335891)
21. Lippert J, Ritz E, Schwarzbeck A, Schneider P (1995) The rising tide of endstage renal failure from diabetic nephropathy type II- an epidemiological analysis. Nephrol Dial Transplant 10: 462-467
22. Liu Y, Pan C, Lu J (1996) The influence of perindopril on intrarenal RAS in experimental diabetic rats. Chung-Hua-II-Hsueh- Tsa-Chih 76 (7): 512-515
23. Luetscher JA, Kraemer FB, Wilson EM, Schwartz HD, Bryer-Ash M (1985) Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 312: 1412-1417 (Pubitemid 15083658)
24. Mann JFE, Mürtz H, Sis J, Usadel KH, Hasslacher CH, Ritz E (1989) Specific binding of angiotensin II and atrial natriuretic factor in non-nephropathic type I diabetes mellitus. Nephrol Dial Transplant 4: 530-534 (Pubitemid 19224869)
25. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P and the cooperative AIPRI (ACE Inhibition in Progressive Renal Insufficiency) Study Group (1996) The effect of the angiotensin converting enzyme inhibitor benazepril on progression of chronic renal insufficiency. New Engl J Med 334 (15): 939-945 (Pubitemid 26114159)
26. Nakamura T, Takahashi T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H (1995) Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 5: 1492-1497
27. National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program (1997) The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure NIH Publication No. 98-4080
28. Okamoto K, Kashihara N, Sugiyama H, Sekikawa T, Maeshima Y, Kanao K, Sato M, Maruyama K, Odawara M, Kasahara J, Sugaya T, Murakami K, Makino H (1997) Suppression of phenotypic alteration of mesangial cells in diabetes induced in angiotensin II type 1a receptor deficient mice. J Am Soc Nephrol A3004: 644A
29. Pohl M, Cooper M, Ulrey J, Pauls J, Rohde R (1997) Safety and efficacy of Irbesartan in hypertensive patients with type II diabetes and protein uria. Amer J Hypertens 10: 105a
30. Pommer W, Bressel F, Chen F, Molzahn M (1997) There is room for improvement of preterminal care in diabetic patients with endstage renal failure. The epidemiological evidence in Germany. Nephrol Dial Transplant 12 (7): 1318-1320 (Pubitemid 27353017)
31. Ravid M, Savin H, Juttrin I (1993) Longterm stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proterinuria in normotensive type II diabetic patients. Ann Intern Med 118 (8): 577-581 (Pubitemid 23102690)
32. Remuzzi A, Fassi A, Sangalli F, Malanchini B, Mohamed EI, Bertani T, Remuzzi G (1998) Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism. Exp Nephrol 6: 28-38 (Pubitemid 28096335)
33. Remuzzi A, Perico N, Amuchastegnui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G (1993) Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4: 40-49
34. Renal Data System, USRDS (1996) Annual Data Report. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease. Bethesda: 1996
35. Ritz E, Fliser D, Nowicki M (1995) Hypertension and Vascular Disease as Complications of Diabetes. In: Laragh JH, Brenner BM (eds) Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition. Raven Press Ltd, New York, pp 2321-2333
36. Ritz E, Koch M, Fliser D, Schwenger V. How to improve prognosis in diabetic patients with endstage renal disease? Diabetes Care (in press)
37. Ritz E, Orth SR, Strzelczyk P (1997) Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens Suppl 15 (2): S21-26 (Pubitemid 27197374)
38. Ritz E, Stefanski A (1996) Diabetic nephropathy in type II diabetes. Am J Kidney Dis 27: 167-194 (Pubitemid 26055128)
39. Rodriguez JA, Cleries M, Vela E (1997) Diabetic patients on renal replacementtherapy: analysis of Catalan Registry data. Nephrol Dial Transplant 12: 2501-2509 (Pubitemid 27520665)
40. Sachinidis A, Sewald S, Ko Y, Feltkamp H, Vetter H (1997) CV-11974, the active metabolite of candesartan cilexetil, inhibits the synergistic effect of PDGF-BB on angiotensin II-induced proliferation of vascular smooth muscle cells. J Hypertens 15 (suppl 4): 54
41. Thieler H, Achenbach H, Bischoff J, Koall W, Kraatz G, Osten B, Smit H (1994) Evolution of renal replacement therapy in East Germany from 1989 to 1992. Nephrol Dial Transplant 9: 238-241 (Pubitemid 24111570)
42. Trenkwalder P, Dahl K, Lehtovirta M, Mulder H (1997) Longterm treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. J Hypertens 10 (4): 85 A
43. Trenkwalder P, Dahl K, Lehtovirta M, Mulder H (1997) Longterm treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. J Hypertens 15 (suppl 4): 202
44. Tschöpe C, Yu M, Reinecke A, Csikos T, Hilgenfeldt U, Pesquero JB, Ritz E, Unger T (1997) Renal expression of two rat kallikrein genes under diabetic conditions. J Hypertension 15: 1711-1714 (Pubitemid 28029669)
45. Viberti GC, Mogensen CE, Groop LC (1994) Effect of captopril on progression to clinical proteinuria in patients with insulindependent diabetes mellitus and microalbuminuria. JAMA 271: 275-279 (Pubitemid 24030753)
46. Von Thun AM, Vari RC, el Dahr SS, Navar LG (1994) Augmentation of intrarenal angiotensin II levels by chronic angiotensin II infusion. Am J Physiol 266: F120-128
47. Wagner J, Gehlen F, Ciechanowicz A, Ritz E. Angiotensin II receptor type II gene expression in human glomerulonephritis and diabetes mellitus (submitted)
48. Wang TT, Wu XH, Zhang SL, Chan JSD (1998) Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells. J Am Soc Nephrol 53: 312-319 (Pubitemid 28097848)
49. Yotsumoto T, Naitoh T, Shikada K, Tanaka S (1997) Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice. Jpn J Pharmacol 75 (1): 59-64 (Pubitemid 27462575)
50. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930 (Pubitemid 16062649)